Medical Condition News

RSS

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Chronic fatigue syndrome (CFS) is characterized by unexplained and debilitating tiredness and is associated with headaches, disrupted sleep, muscle pain and difficulty in concentrating. New research published by BioMed Central's open access journal BMC Medicine shows that ethnicity, depression, lack of exercise or social support, and social difficulties are major risk factors for CFS.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Researchers baffled with increase in migraine rates

Migraine rates in a comprehensive Norwegian health study have climbed by 1% in a decade -- that may not sound like much, but in the Norwegian context, it means 45,000 more migraine sufferers -- and if the trend were to hold for the European Union, that would be an additional 5 million more people plagued by migraines. Researchers at the Norwegian University of Science and Technology (NTNU) are baffled by the cause of this trend.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

Researchers discover 'broad spectrum' cancer suppressor gene

Portuguese researchers have discovered a "broad spectrum" cancer suppressor gene - called LRP1B - which acts by removing proteins crucial for cancer development from the tumour environment. The fact that LRP1B does not act on the tumour itself (in this study thyroid tumours) but, instead, on molecules which are known to be important to many different cancers is what makes it so interesting.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

Onset of chronic pain more often reported following a traffic accident

Individuals with poorer health or psychological issues may be prone to developing chronic widespread pain following a traumatic event. This new research, published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), found that the onset of chronic pain was more often reported following a traffic accident than from other physically traumatic triggers.

21 Mar 2011

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

Asthma an diabetes go hand in hand: Research

A new study has found that people with asthma may have a higher risk of developing diabetes and heart disease. The study looked at the relationship between asthma and four other inflammatory conditions.

21 Mar 2011

JCCF event honors Showtime Networks President with Humanitarian Award

The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.

19 Mar 2011

Researcher to present study on validation of salivary-biomarkers for pSS patients

Saturday, March 19, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher A.N.M. Nazmul-Hossaini will hold an oral presentation on a study titled "Validation of Salivary-Biomarkers for Sj-gren's Syndrome Detection in US Population."

19 Mar 2011

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

19 Mar 2011

Insight into hereditary diseases

Hereditary diseases such as epilepsy or various coordination disorders may be caused by changes in nerve cells of the cerebellum, which do not set in until after birth. This is reported by Bochum's neuroscientists in the Journal of Neuroscience.

19 Mar 2011

U-M professor shows how plasticity of brain restores critical functions related to learning, memory

When Geoffrey Murphy, Ph.D., talks about plastic structures, he's not talking about the same thing as Mr. McGuire in The Graduate. To Murphy, an associate professor of molecular and integrative physiology at the University of Michigan Medical School, plasticity refers to the brain's ability to change as we learn.

19 Mar 2011

Are newer prostate cancer treatments — now gaining popularity — worth the extra cost?

Newer technologies for treating prostate cancer have surged in popularity in the last decade — and they have come with a hefty price tag, according to a report published this week.

19 Mar 2011

Celebrity Chefs Cook Gala to support cancer research at UC San Diego

Top celebrity chefs from around the country will gather in San Diego April 16 for the 30th Celebrity Chefs Cook Gala benefiting research at the UC San Diego Moores Cancer Center. Themed "Epicurean Elegance: Food for the Mind, Body and Spirit," the gala will feature lush food artistry as 11 premiere chefs prepare their signature hors d'oeuvres paired with fine wine. Proceeds from the event will support the cancer center's most urgent needs.

19 Mar 2011

ACRIN, ECOG, NCI intent to merge their clinical cancer research programs

The American College of Radiology's Imaging Network and the Eastern Cooperative Oncology Group, National Cancer Institute Clinical Trials Cooperative Group members, today announced their intent to merge their clinical cancer research programs.

19 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

Medical Condition News

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Researchers baffled with increase in migraine rates

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

Researchers discover 'broad spectrum' cancer suppressor gene

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Onset of chronic pain more often reported following a traffic accident

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Asthma an diabetes go hand in hand: Research

JCCF event honors Showtime Networks President with Humanitarian Award

Researcher to present study on validation of salivary-biomarkers for pSS patients

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

Insight into hereditary diseases

U-M professor shows how plasticity of brain restores critical functions related to learning, memory

Are newer prostate cancer treatments — now gaining popularity — worth the extra cost?

Celebrity Chefs Cook Gala to support cancer research at UC San Diego

ACRIN, ECOG, NCI intent to merge their clinical cancer research programs

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News